Bladder cancer is a heterogeneous disease, with 70% of patients presenting with superficial
tumours, which tend to recur but are generally not life threatening, and 30% presenting as …

Bladder cancer is the second most common genitourinary tumour and is a significant cause
of morbidity and mortality. Trials of neoadjuvant and adjuvant chemotherapy have failed to …

Bladder cancer is a complex disease associated with high morbidity and mortality rates if not
treated optimally. Awareness of haematuria as the major presenting symptom is paramount …

This Seminar presents the current best practice for the diagnosis and management of
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …

Although muscle-invasive bladder cancer is commonly treated with radical cystectomy, a
standard alternative is bladder preservation therapy, consisting of maximum transurethral …

Seventy to eighty percent of patients with newly-diagnosed bladder cancer will present with
superficial tumors (Ta, Tis or T 1). There is, however, a continuum between superficial and …

Background We assessed effectiveness, safety, and tolerability of paclitaxel or fluorouracil
when added to radiation plus cisplatin followed by adjuvant chemotherapy in a programme …

Context We present an overview of the updated 2023 European Association of Urology
(EAU) guidelines for muscle-invasive and metastatic bladder cancer (MMIBC). Objective To …

Standard treatment for muscle-invasive bladder cancer is cystectomy. Trimodality treatment,
including transurethral resection of the bladder tumor (TURBT), radiation therapy and …

CONTEXT: New data regarding treatment of muscle-invasive and metastatic bladder cancer
(MiM-BC) has emerged and led to an update of the European Association of Urology (EAU) …